<DOC>
	<DOCNO>NCT01708044</DOCNO>
	<brief_summary>To examine effect different fix pramlintide : insulin dose ratio subject type 1 diabetes postprandial plasma glucose concentration</brief_summary>
	<brief_title>Effect Different Fixed Pramlintide : Insulin Dose Ratios Postprandial Glucose T1DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Is 18 70 year old Is male , female meet follow criterion : 1 . Not breastfeed 2 . Negative pregnancy test result , childbearing potential , must practice willing continue practice appropriate birth control Has diagnose type 1 diabetes mellitus least 1 year achieve glycemic goal MDI insulin Has HbA1c 7.0 % 9.0 % Has MDI regular insulin , dose exceed 10 units/breakfast least 3 month continuous subcutaneous insulin infusion ( CSII ) , dose exceed 10 units/breakfast , least 3 month willing switch MDI insulin regimen 1 day prior enrollment study Has body mass index ( BMI ) &lt; 30 kg/m2 Has experience recurrent severe hypoglycemia require assistance within 6 month Visit 1 Screening Has history hypoglycemia unawareness Has confirm diagnosis gastroparesis Has treat , currently treat , expect require undergo treatment follow medication : 1 . Any antihyperglycemic agent insulin 2 . Drugs directly affect gastrointestinal motility ( e.g. , anticholinergic agent atropine ) 3 . Drugs slow intestinal absorption nutrient ( e.g. , Î±glucosidase inhibitor . Has clinically significant medical condition could potentially affect study participation and/or personal wellbeing , judge investigator , include limited following condition : 1 . Hepatic disease 2 . Renal disease 3 . Gastrointestinal disease 4 . Pulmonary disease 5 . Organ transplantation 6 . Chronic infection ( e.g. , tuberculosis , human immunodeficiency virus , hepatitis B virus , hepatitis C virus ) Is currently treat previously treat SYMLIN/pramlintide participate SYMLIN/pramlintide clinical study within 3 month Visit 1 ( Screening ) . Has clinically significant laboratory finding medical history may affect successful completion study and/or personal wellbeing Has donate blood within 2 month plan donate blood study . Has major surgery blood transfusion within 2 month Has receive investigational drug within 1 month Has know allergy hypersensitivity component study treatment . Is immediate family member personnel directly affiliate study clinical study site , directly affiliate study clinical study site . Is employed Amylin Pharmaceuticals , Inc ( Amylin ) ( employee , temporary contract worker , designee responsible conduct study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pramlintide ,</keyword>
	<keyword>insulin ,</keyword>
	<keyword>type 1 diabetes ,</keyword>
	<keyword>reduction postprandial glucose ,</keyword>
	<keyword>pramlintide : insulin dose-ratio</keyword>
</DOC>